¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"methyl dopa therapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® family therapy ÇÑ±Û °¡Á·¿ä¹ý
¼³¸í   
  °¡Á·À» Ä¡·á ´ë»óÀ¸·Î Çϴ ½É¸®¿ä¹ý ÁßÀÇ Çϳª. °¡Á·ÁßÀÇ ¹®Á¦´Â ¹®Á¦¸¦ °¡Áø °³Àθ¸ÀÌ ¾Æ´Ï¶ó ¹®Á¦ °¡Á·À» ´ë»óÀ¸·Î ÇذáÇØ ³ª°¥ Çʿ䰡 Àִٴ ÀνÄÀ» ¹ÙÅÁÀ¸·Î ÇÏ¿© °¡Á· ÀüüÀÇ ½É¸®Àû ¼º¼÷À» ¸ñÇ¥·Î ÇÑ ¿ä¹ýÀÌ´Ù. Å©°Ô ³ª´©¾î °¡Á· ÁßÀǠƯÁ¤ÀÎÀ» ´ë»óÀ¸·Î ÇÏ¿© °¢°¢ ´Ù¸¥ µ¶¸³µÈ Ä¡·á¸¦ Çϴ º´Çà½É¸®¿ä¹ý°ú °¡Á· Àüü¸¦ µ¿½Ã ¸éÁ¢Çϴ ¹æ¹ýÀ» ÁַΠÇϴ ÇÕµ¿°¡Á·¿ä¹ýÀÌ Àִµ¥, Æ¯È÷ ÈÄÀÚ¸¦ °¡¸®ÄÑ °¡Á·¿ä¹ý À̶ó°í Çϴ °æ¿ì°¡ ¸¹´Ù.
¿µ¹® intracavitary therapy ÇÑ±Û °­³»¿ä¹ý
¼³¸í   
  Ã¼°­³», Áï ÀÔ¾È, ÄÚ¾È, Àεΰ­, ½Äµµ, °ðâÀÚ, Áú, Àڱøñ, ¹æ±¤ µîÀÇ ³»°­¿¡, ¶§·Î´Â º´ÅÍ¿¡ ÀÇÇØ »ý±ä °øµ¿³»¿¡ ¹æ»ç¼±À» »ðÀÔÇØ¼­ Ä¡·áÇϴ °ÍÀ» ¸»ÇÑ´Ù. ÁַΠÁ¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ´Ù.
¿µ¹® hyperbaric oxygenation therapy ÇÑ±Û °í¾Ð»ê¼Ò¿ä¹ý
¼³¸í   
  ´ë±â¾Ðº¸´Ù ³ôÀº ±â¾Ðȯ°æÀ» ÀΰøÀûÀ¸·Î ¸¸µé¾î ±× ¾È¿¡¼­ °í³óµµÀÇ »ê¼Ò¸¦ ÈíÀÔ½Ã۴ ¿ä¹ý. Çѱ¹¿¡¼­ ¿¬Åº°¡½º·Î ´ëÇ¥µÇ´Â ÀÏ»êȭź¼ÒÀÇ ±Þ¼ºÁßµ¶ÀÇ Ä¡·á¿¡ ¸¹ÀÌ ÀÌ¿ëµÈ °ÍÀ¸·Î, º¸Åë 3´ë±â¾Ð Á¤µµ·Î °¡¾ÐµÈ °í¾Ð»ê¼Ò½ÇÀ̳ª °í¾Ð»ê¼ÒÅÊÅ© ¼Ó¿¡ È¯ÀÚ¸¦ ³õ°í Àü½Å¿¡ »ê¼Ò¸¦ ÈíÀÔ½ÃŲ´Ù. °í¾Ð½ÇÀº Å©°í ÀÛÀº ¿©·¯ °¡Áö°¡ ÀÖÀ¸¸ç, ±¸Á¶»ó 1½Ç½Ä-2½Ç½Ä-´Ù½Ç½ÄÀÌ ÀÖ´Ù. °¡¾Ð °¡½ºÀÇ Á¾·ù¿¡´Â »ê¼Ò-°ø±â-È¥ÇÕ °¡½ºµîÀÌ ÀÖ°í, 2~3 ´ë±â¾Ð ¶Ç´Â ±× ÀÌ»óÀÇ °í¾Ð È¯°æÀ» ¸¸µç´Ù. ÀÓ»óÀûÀ¸·Î ÀÀ¿ë¹üÀ§°¡ ³Ð¾î¼­ ±â°èÀû È¿°ú¿¡ ÀÇÇÏ¿© Àá¼öºÎº´À̳ª Ã¢ÀÚ°ü¸¶ºñ¿¡ ÀÇÇѠâÀÚÆó»ö Ä¡·á µî¿¡ À¯È¿Çϰí, °¡½º±ËÀú µîÀÇ ¹«»ê¼Ò¼º ¼¼±Õ°¨¿°¿¡¼­µµ ÀÌ¿ëµÈ´Ù. ¶Ç »ê¼Ò¿î¹ÝÈ¿°ú¿¡ ÀÇÇÏ¿© ÀÏ»êȭź¼Ò-½É±Ù°æ»ö-³ú»öÀüÁõ-ÃâÇ÷¼îÅ©¿¡ ÀÇÇÑ ±Þ¼ºÀÇ Á¶Á÷»ê¼Ò°áÇÌÀÇ Ä¡·á¿¡ À¯È¿ÇÏ´Ù. ¶Ç ¾ÏÀÇ ¹æ»ç¼±¿ä¹ý¿¡ º´¿ëÇϸé ÀÌ ¿ä¹ýÀ¸·Î ¾Ï¼¼Æ÷ÀÇ ºÐ¿­ÀÌ ¿Õ¼ºÇØÁ®, ¼¼Æ÷ºÐ¿­ ÁßÀΠ¼¼Æ÷¿¡ ¹æ»ç¼±À» Á¶»çÇÔÀ¸·Î½á ºÐ¿­´É·ÂÀ» ¾ø¾Ö´Â µ¥ À¯È¿ÇÏ¿© °í¾Ð»ê¼ÒÈíÀÔÁ¶»ç¹ýÀ̶ó°í ÇÑ´Ù.
¿µ¹® interstitial therapy ÇÑ±Û ±ÙÁ¢Ä¡·á
¼³¸í   
  ÁַΠÁ¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ¿© ÀÎü Á¶Á÷³»¿¡ ¹æ»ç¼± ¹°ÁúÀ» »ðÀÔÇÏ¿© ¹æ»ç¼±À» Á¶»çÇϴ ġ·á¹ýÀÌ´Ù. Brachytherapy¶ó°íµµ ÇÑ´Ù.
¿µ¹® symptomatic therapy ÇÑ±Û ´ëÁõ¿ä¹ý
¼³¸í   
  º´ÀÇ ¿øÀÎÀ» Ã£¾Æ ¾ø¾Ö±â °ï¶õÇÑ »óȲ¿¡¼­, °ÑÀ¸·Î ³ªÅ¸³­ º´ÀÇ Áõ»ó¿¡ ´ëÀÀÇÏ¿© Ã³Ä¡¸¦ Çϴ ġ·á¹ý. ¿­ÀÌ ³ôÀ» ¶§¿¡ ¾óÀ½ÁָӴϸ¦ ´ë°Å³ª ÇØ¿­Á¦¸¦ ½á¼­ ¿­À» ³»¸®°Ô Çϴ µûÀ§°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopa
    µµÆÄ
  • dopa reaction
    µµÆÄ¹ÝÀÀ
  • methyl alcohol
    ¸ÞÆ¿¾ËÄÚ¿Ã
  • methyl group
    ¸ÞÆ¿±â
  • antibiotic therapy
    Ç×»ýÁ¦¿ä¹ý
  • acetylsalycylic acid antiplatelet therapy
    ¾Æ¼¼Æ¿»ì¸®½Ç»êÇ×Ç÷¼ÒÆÇ¿ä¹ý
  • acid therapy
    »ê¿ä¹ý
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • behavioral therapy
    Çൿ¿ä¹ý
  • biologic therapy
    »ý¹°ÇÐÀûÁ¦Á¦¿ä¹ý
  • client-centered therapy
    ³»´ãÀÚÁ߽ɿä¹ý, ÀÇ·ÚÀÎÁ߽ɿä¹ý
  • cognitive therapy
    ÀÎÁö¿ä¹ý
  • cold therapy
    ÇÑ·©¿ä¹ý, Àú¿Â¿ä¹ý
  • combined modality therapy
    º´¿ë¿ä¹ý
  • compression therapy
    ¾Ð¹Ú¿ä¹ý
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • methyl prednisolone
    ¸ÞÆ¿ÇÁ·¹µå´Ï¼Ö·Ð
  • therapy
    ¿ä¹ý
  • acetylsalycylic acid antiplatelet therapy
    Ç×Ç÷¼ÒÆÇ¿ä¹ý
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • antibiotic therapy
    Ç×»ýÁ¦¿ä¹ý
  • ASA antiplatelet therapy
    (¢¡acetylsalycylic acid antiplatelet therapy) Ç×Ç÷¼ÒÆÇ¿ä¹ý
  • behavioral therapy
    Çൿ¿ä¹ý
  • electroconvulsive therapy
    Àü±â°æ·Ã¿ä¹ý
  • estrogen replacement therapy
    ¿©¼ºÈ£¸£¸ó´ëü¿ä¹ý
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • home oxygen therapy
    °¡Á¤»ê¼Ò¿ä¹ý
  • initial therapy
    ÃʱâÄ¡·á
  • O2 therapy
    »ê¼Ò¿ä¹ý
  • radiation therapy
    ¹æ»ç¼±¿ä¹ý, ¹æ»ç¼±Ä¡·á
  • replacement therapy
    ´ëÄ¡¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopa
    µµÆÄ
  • dopa reaction
    µµÆÄ¹ÝÀÀ
  • methyl alcohol
    ¸ÞÆ¿¾ËÄÚ¿Ã
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â
  • methyl group
    ¸ÞÆ¿±â
  • activity therapy
    Ȱµ¿¿ä¹ý
  • adaptive radiation therapy
    ÀûÀÀ¹æ»ç¼±Ä¡·á, ¼øÀÀ¹æ»ç¼±¿ä¹ý
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • microwave therapy apparatus
    ±ØÃÊ´ÜÆÄÄ¡·á±â
  • bacterial interference therapy
    ¼¼±Õ°£¼·¿ä¹ý
  • behavioral therapy
    Çൿ¿ä¹ý
  • biologic therapy
    »ý¹°ÇÐÀûÁ¦Á¦¿ä¹ý
  • boron-neutron capture therapy
    º¸·ÐÁß¼ºÀÚÆ÷ȹ¿ä¹ý
  • client-centered therapy
    ³»´ãÀÚÁ߽ɿä¹ý, ÀÇ·ÚÀÎÁ߽ɿä¹ý
  • cognitive therapy
    ÀÎÁö¿ä¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DOPA
    µµÆÄ
  • L-DOPA
    L-µµÆÄ
  • Chelation therapy
    ų·¹ÀÌÆ® ¿ä¹ý
  • ECT=Electroconvulsive Therapy
    Àü±â°æ·Ã¿ä¹ý
  • EST See Electroshock therapy
    Àü±âÃæ°Ý¿ä¹ý(ï³Ñ¨õú̪èþÛö)
  • Gene therapy
    À¯ÀüÀÚÄ¡·á(ö½Öû)
  • RePUVA therapy
    ·¹Æ¼³ëÀ̵å+PUVA
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • activity therapy
    Ȱµ¿ ¿ä¹ý
  • acupuncture therapy
    ħ¼ú¿ä¹ý.
  • adaptive radiation therapy
    ÀûÀÀ¹æ»ç¼±Ä¡, ¼øÀÀ¹æ»ç¼±Ä¡·á
  • adjuvant therapy
    º¸Á¶¿ä¹ý.
  • adjuvant therapy
    º¸Á¶¿ä¹ý, º¸Á¶Ä¡·á
  • androgen therapy
    ³²¼ºÈ£¸£¸ó ¿ä¹ý
  • antiandrogenic therapy
    Ç׳²¼ºÈ£¸£¸ó¿ä¹ý.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • methyl dopa therapy
    ¸ÞÆ¿µµÆÄÄ¡·á(¡­ö½èþ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • methyl dopa
    ¸ÞÆ¿µµÆÄ.
  • dihydroxyphenylalanine(DOPA)
  • dopa reaction
    µµÆÄ ¹ÝÀÀ
  • dopa stain
    µµÆÄ ¿°»ö
  • dopa-oxidase
    µµÆÄ»êÈ­È¿¼Ò(¡­ß«ûùý£áÈ).
  • chloromethyl methyl ether
    Ŭ·Î·Î¸ÞÅÚ¿¡Å׸£
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â.
  • methyl alcohol
    ¸ÞÆ¿¾ËÄÝ.
  • methyl alcohol
    ¸ÞÆ¿¾ËÄÚ¿Ã
  • methyl alcohol intoxication
    ¸ÞÆ¿¾ËÄÝÁßµ¶.
  • methyl group
    ¸ÞÆ¿±â.
  • methyl nicotinamide
    ¸ÞÆ¿´ÏÄÚÆ¾¾Æ¹Ìµå.
  • methyl pentosan
    ¸ÞÆ¿ÆæÅä»ê.
  • methyl prednisolone
    ¸ÞÆ¿ÇÁ·¹µå´Ï¼Ö·Ð.
  • methyl red test
    ¸ÞÆ¿·¹µå°Ë»ç
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malarial therapy
    ¸»¶ó¸®¾Æ¿ä¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DOPA
    "(å²) 3,4-dihydroxyphenylalanine"
  • antidotal therapy
    Ç×ÇØµ¶Ä¡·á(ù÷ú°Ô¸ö½Öû)
  • enzyme replacement therapy
    È¿¼Ò ´ëü Ä¡·á (ý£áÈÓÛôðö½Öû)
  • enzyme therapy
    È¿¼ÒÄ¡·á (ý£áÈö½Öû)
  • gene therapy
    À¯ÀüÀÚ Ä¡·á(ë¶îîí­ö½Öû)
  • active methyl
    Ȱ¼º(üÀàõ)¸ÞÆ¿
  • angle methyl group
    ¾Þ±Û¸ÞÆ¿±â(Ðñ)
  • catechol-O-methyl transferase
    Ä«Å×ÄÝ-0-¸ÞÆ¿ Æ®¶õ½ºÆÛ·¹À̽º
  • labile methyl group
    ºÒ¾ÈÁ¤(ÝÕäÌïÒ)¸ÞÆ¿±â(Ðñ)
  • O-methyl derivative
    O-¸ÞÆ¿À¯µµÃ¼(ë¯Óôô÷)
  • methyl green
    ¸ÞÆ¿±×¸°
  • methyl group
    ¸ÞÆ¿±â(Ðñ)
  • methyl-poor transfer RNA
    °ú(Íû)¸ÞÆ¿ Àü´Þ(îîÓ¹)RNA
  • N5-methyl tetrahydrofolic acid
    N5-¸ÞÆ¿»ç¼ö¼ÒÆú»ê(ß«)
  • methyl-trap hypothesis
    ¸ÞÆ¿Æ÷ȹ¼³(øÚüòàã)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • isotope therapy
    µ¿À§¿ø¼ÒÄ¡·á
  • maintenance therapy
    À¯Áö¿ë¹ý
  • percutaneous ethanol injection therapy
    °æÇÇÀû¿¡Å¸³îÁÖÀÔ¿ä¹ý
  • radiation therapy
    ¹æ»ç¼±Ä¡·á
  • radium therapy
    ¶óµãÄ¡·á
  • replacement therapy
    º¸»ó¿ä¹ý, ´ëÄ¡¿ä¹ý
  • therapy
    Ä¡·á, ¿ä¹ý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DOPA, dopa dihydroxyphenylalanine
L-DOPA, L-dopa levodopa, levo-3, 4-dihydroxyphenylalanine
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
IT immunological test; immunotherapy; implantation test; individual therapy; information technology; in...
MT magnetization transfer; malaria therapy; malignant teratoma; mammary tumor; mammilothalamic tract; m...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
(18)F-DOPA 6-[(18)F]fluoro-L-DOPA
L-DOPA L-Dihydroxphenylalanine
6-FD 18F]6-fluoro-L-dopa
DOPA 3,4-dihydrophenylalanine
DA DOPA and dopamine
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • methyl dopa
    ¸ÞÆ¿ µµÆÄ
    3-hydroxy-al
  • methyl green-pyronin of nucleolus

    methyl group

    ¸ÞÄ¥±â
  • dopa decarboxylase inhibitor
    µµÆÄ µ¥Ä«¸£º¹½Ç·¹À̽º ¾ïÁ¦ÀÚ
  • dopa stain
    µµÆÄ ¿°»ö
  • L-dopa
    L-µµÆÄ
    levodo
  • catechol-o-methyl transferase
    catechol-o-methyl ÀüÀÌ È¿¼Ò
    ¿¡Çdz×ÇÁ¸°°ú ³ë¸£¿¡Çdz×ÇÁ¸°À» ºñȰ¼ºÈ­½ÃŰ´Â È¿¼Ò.
  • dihydroxy-propoxy-methyl guanine
    ´ÙÀÌÇÏÀ̵å·Ï½Ã-ÇÁ·ÎÆø½Ã-¸ÞÆ¿ ±¸¾Æ´Ñ
  • methyl
    ¸ÞÄ¥, ¸ÞÆ¿±â
    È­ÇÐ ¿øÀÚ´Ü ¶Ç´Â ±â.
  • methyl alcohol intoxication
    ¸ÞÆ¿ ¾ËÄÚ¿Ã Áßµ¶
    ¸ÞÆ¿ ¾ËÄÚ¿Ã
  • methyl-methacrylate
    ¸ÞÆ¿ ¸ÞŸ¾ÆÅ©¸±·¹ÀÌÆ®
    C
  • acrylic splint therapy
    ¾ÆÅ©¸± ¾ÈÁ¤ ±³ÇÕ»ó Ä¡·á
  • active relaxation therapy
    ´Éµ¿ ÀÌ¿Ï ¿ä¹ý
  • adaptive radiation therapy
    ÀûÀÀ ¹æ»ç¼± Ä¡·á, ¼øÀÀ ¹æ»ç¼± Ä¡·á
  • adjunctive therapy
    ºÎ°¡ ¿ä¹ý
    ÁÖµÈ Ä¡·á °úÁ¤ ÀÌ¿ÜÀÇ Ãß°¡ Ä¡·á °úÁ¤.
  • adjuvant therapy
    º¸Á¶ ¿ä¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
alpha methyl dopa <drug> An antihypertensive drug, preferred in pregnant patients.
(18 Nov 1997)
decarboxylated dopa <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline.
Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance
Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output
Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min.
Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias
(15 Mar 2000)
dopa An amino acid derived from the amino acid tyrosine. It is formed as the first intermediate in the production of dopamine, a neurotransmitter.
(09 Oct 1997)
dopa decarboxylase <enzyme> One of the aromatic-l-amino-acid decarboxylases, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of parkinson's disease.
Registry number: EC 4.1.1.-
(12 Dec 1998)
DOPA dioxygenase <enzyme> Key enzyme in betalain biosynthesis pathway of amanita muscaria; genbank y12886
Registry number: EC 1.14.99.-
Synonym: dopa-4,5-dioxygenase, doda gene product
(26 Jun 1999)
dopa oxidase Provisional name given the enzyme(s) catalyzing the formation of melanins from dopa; it now appears that the copper-containing monophenol monooxygenases and/or catechol oxidases are responsible for the oxidation of l-tyrosine to dopa and dopa quinone.
(05 Mar 2000)
dopa quinone An oxidation product of dopa and an intermediate in the formation of melanin from tyrosine.
(05 Mar 2000)
dopa reaction A dark staining observed in fresh tissue sections to which a solution of dopa has been applied, presumably due to the presence of dopa oxidase in the protoplasm of certain cells.
Synonym: Bloch's reaction.
(05 Mar 2000)
dopa-responsive dystonia A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy.
(12 Dec 1998)
Dopa-tyrosine sulfotransferase <enzyme> Active towards tyrosine and dopa isomers except dl-ortho-tyrosine; isolated from rat liver; genbank u38419
Registry number: EC 2.8.2.-
(26 Jun 1999)
dystonia, dopa-responsive A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy.
(12 Dec 1998)
l-dopa <chemical> The naturally occurring form of dopa and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonism and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
Pharmacological action: antiparkinson agents, dopamine agents.
(12 Dec 1998)
L-dopa peroxidase <enzyme> Found in human erythrocytes associated with catalase
Registry number: EC 1.11.-
(26 Jun 1999)
active methyl A methyl group attached to a quaternary ammonium ion or a tertiary sulfonium ion that can take part in transmethylation reactions; e.g., methyl groups in choline and in S-adenosyl-l-methionine, which are thus methyl donors.
(05 Mar 2000)
aklanonic acid methyl ester cyclase <enzyme> Catalyses the formation of aklaviketone from aklanonic acid methyl ester; involved in daunomycin biosynthesis; see also daunorubicin-doxorubicin polyketide synthase
Registry number: EC 5.-
Synonym: aame cyclase, daud protein, daud gene product, dnrd protein, dnrd gene product
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopa
    ¾Æ¹Ì³ë»êÀÇÀÏÁ¾
  • methyl
    ¸ÞÆ¿
  • methyl alcohol
    ¸ÞÆ¿¾ËÄÚ¿Ã
  • methyl blue
    ¸Þƿû(û»öÀÇ À¯±â¿°·á,Çʱâ¿ë À×Å©³ª »ýü ¿°»ö¿¡ ¾¸)
  • methyl chloride
    ¿°È­ ¸ÞÆ¿
  • methyl chloridep
    ¿°È­ ¸ÞÆ¿
  • therapy
    Ä¡·á; ¿ä¹ý
  • Xray therapy
    ¿¢½º¼± ¿ä¹ý
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cellar therapy
    =CELL THERAPY
  • deep therapy
    ½ÉºÎ X¼± Ä¡·á(ÁÖ´ë»óÀº ¾Ç¼º Á¾¾ç)
  • electric shock therapy
    (Á¤ÀÇ)Àü±â ¼îÅ©¿ä¹ý
  • electroconvulsive therapy
    =ELECTROSHOCK THERAPY
  • electroshock therapy
    (Á¤ÀÇ)Àü±â ¼îÅ©(Ãæ°Ý)¿ä¹ý
  • family therapy
    °¡Á· ¿ä¹ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á